Core Viewpoint - The company, Shenlian Biopharmaceutical (Shanghai) Co., Ltd., has signed a project contract with the Lanzhou Veterinary Research Institute to jointly develop multi-valent vaccines for swine and cattle, aiming to enhance disease prevention efficiency and reduce costs [1]. Group 1: Project Collaboration - The collaboration involves the development of multi-valent vaccines targeting three diseases for pigs and three for cattle, with both parties sharing the resulting technology and intellectual property [1]. - Each party will bear its respective costs as per the agreement, indicating a structured approach to resource allocation [1]. Group 2: Market Competitiveness - The anticipated vaccines are expected to achieve "one injection for four protections," which will reduce the number of immunizations required, thereby saving resources and costs while improving production efficiency [1]. - This initiative is projected to enhance the company's competitive edge in the animal health sector by providing comprehensive and efficient disease prevention solutions [1]. Group 3: Future Development Plans - The company plans to strengthen its collaboration with the Lanzhou Veterinary Research Institute, keeping pace with industry trends and accurately addressing changes in prevalent strains and clinical needs [1]. - Future efforts will focus on exploring the application potential of its R&D technology platform, accelerating breakthroughs in other multi-valent vaccines, mRNA vaccines, synthetic peptide vaccines, and virus-like particle (VLP) vaccines [1]. - The goal is to gradually form a clustered product matrix in disease prevention for pigs, ruminants, pets, and aquaculture, continuously enhancing the company's core competitiveness [1].

Major Events - Water Well Square: Director Sathish Krishnan resigned due to work reasons, and will no longer hold any position in the company [1] - Victory Energy: The company reported normal operating conditions with no significant changes in the internal and external business environment [1] Investments - Dream Network Technology: The company plans to jointly invest in a private equity fund with a target fundraising scale of 2 billion yuan, with the company contributing 50 million yuan [2] - Guoen Co., Ltd.: The company has completed the development of PEEK material production technology and aims to establish a vertical integration platform for the entire PEEK industry chain [2] Performance - Action Education: The controlling shareholder proposed a mid-term dividend of 10 yuan per 10 shares for the 2025 fiscal year [3] - Jiejia Weichuang: The company expects a net profit of 1.7 billion to 1.96 billion yuan for the first half of 2025, representing a year-on-year increase of 38.65% to 59.85% [3] - Sinopec: The company anticipates a net profit of 20.1 billion to 21.6 billion yuan for the first half of 2025, a decrease of 39.5% to 43.7% year-on-year due to various market pressures [4] - Daodaquan: The company reported a net profit of 181 million yuan for the first half of 2025, a year-on-year increase of 563.15% [4] - New Light Optoelectronics: The company expects a loss of 19 million to 23 million yuan for the first half of 2025, with revenue declining significantly [4] Contracts and Collaborations - Shunlian Bio: The company signed contracts for the development of multi-valent vaccines in collaboration with the Chinese Academy of Agricultural Sciences [4] - Boying Special Welding: The company signed a cooperation framework agreement with Suzhou Weirhan to collaborate in special welding technology applications [5] Shareholding Changes - Jiangnan Yifan: The company's director and general manager plans to increase shareholding by purchasing between 50,000 and 100,000 shares from August 1, 2025, to January 31, 2026 [6]

Core Viewpoint - The company, Shenlian Biological (688098.SH), has signed cooperative contracts with the Lanzhou Veterinary Research Institute of the Chinese Academy of Agricultural Sciences and other entities to develop multi-valent vaccines for swine and cattle, focusing on several significant diseases [1] Group 1: Vaccine Development Contracts - The company has entered into two contracts for the technical development of vaccines: one for swine diseases including foot-and-mouth disease (O-type/A-type), swine fever, and pseudorabies, and another for cattle diseases including foot-and-mouth disease (O-type/A-type), viral diarrhea/mucosal disease, and infectious bovine rhinotracheitis [1] - The collaboration involves shared responsibilities and costs among the parties according to the agreements, with the resulting technological achievements and intellectual property being jointly owned by the company and the Lanzhou Veterinary Research Institute [1]

Core Viewpoint - The company, Shenlian Biological (688098), has signed cooperative contracts with the Lanzhou Veterinary Research Institute of the Chinese Academy of Agricultural Sciences to develop multi-valent vaccines for swine and cattle diseases [1] Group 1: Vaccine Development Contracts - The company has entered into two contracts for the technical development of vaccines: one for swine diseases including foot-and-mouth disease (O-type/A-type), swine fever, and pseudorabies, and another for cattle diseases including foot-and-mouth disease (O-type/A-type), viral diarrhea/mucosal disease, and infectious bovine rhinotracheitis [1] - The collaboration involves shared responsibilities and costs among the parties involved, with the resulting technological achievements and intellectual property being jointly owned by the company and the Lanzhou Veterinary Research Institute [1]

Core Viewpoint - The company has signed cooperative contracts with the Lanzhou Veterinary Research Institute of the Chinese Academy of Agricultural Sciences and other units to develop multi-valent vaccines for swine and cattle, focusing on several significant diseases [1] Group 1: Vaccine Development Contracts - The company has entered into a contract for the technical development of a tri-valent vaccine for swine, targeting foot-and-mouth disease (FMD) types O and A, swine fever, and pseudorabies [1] - Additionally, a contract has been signed for the development of a tri-valent vaccine for cattle, addressing FMD types O and A, viral diarrhea/mucosal disease, and infectious bovine rhinotracheitis [1] - The collaboration involves shared responsibilities and costs among the parties, with the resulting technological achievements and intellectual property being jointly owned by the company and the Lanzhou Veterinary Research Institute [1]

Core Viewpoint - The company has signed cooperative contracts with the Lanzhou Veterinary Research Institute of the Chinese Academy of Agricultural Sciences and other entities to develop multi-valent vaccines for swine and cattle diseases, indicating a strategic move to enhance its vaccine portfolio and collaborative research efforts [1] Group 1 - The company is collaborating on the development of a tri-valent vaccine for swine diseases including Foot-and-Mouth Disease (FMD) type O/A, Classical Swine Fever (CSF), and Pseudorabies [1] - The company is also involved in the development of a tri-valent vaccine for cattle diseases including FMD type O/A, Viral Diarrhea/Mucosal Disease, and Infectious Bovine Rhinotracheitis [1] - The collaboration entails shared responsibilities and costs among the parties involved, with the resulting technological achievements and intellectual property being jointly owned by the company and the Lanzhou Veterinary Research Institute [1]